NEW YORK (GenomeWeb) – Myriad Genetics reported after the close of the market Tuesday a 17 percent year-over-year increase in its revenues driven by its hereditary cancer tests.

For the three months ended March 31, Myriad reported total revenues of $182.9 million, up from $156.5 million in the third quarter of fiscal year 2013. The firm easily beat the consensus analysts' estimate of $175.3 million.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

Researchers find that a personalized medicine approach could help people who experience pain while taking statins, New Scientist reports.

US National Science Foundation is continuing its responsible research conduct training policy despite its flaws, ScienceInsider reports.

A CRISPR-themed meeting explored how the tool could and should be used, Wired reports.

In Science this week: database of proteins' effects on cancer, targeted error correction sequencing, and more.